Milestone Scientific (MLSS)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • AMEX
Market Cap: $26.64M
Last updated: Nov 17, 2026 at 4:10 PM ET
Milestone Scientific (MLSS) Statistics
Milestone Scientific (MLSS) has a market cap of $26.64M and an enterprise value of $25.32M. Its share count is up 14.08% from a year earlier. It kept -40.27% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 4.94% below the market cap, as cash exceeds debt.
| Market Cap | $26.64M |
|---|---|
| Enterprise Value | $25.32M |
| Latest price (Nov 17, 2026) | $0.28 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.9x and 7.3x. Its year-end P/S ranged from 1.3x to 23.1x from 2016 to 2025.
| P/S Ratio | 2.9x |
|---|---|
| Forward P/S | 2.7x |
| P/B Ratio | 7.3x |
| P/TBV Ratio | 7.3x |
Price Statistics
The stock is down 14.39% over 52 weeks and trades 20.00% below its 50-day average.
| Beta (1Y) | 1.26 |
|---|---|
| 52-Week Change | -14.39% |
| 1-Month Change | -15.17% |
| 3-Month Change | -39.91% |
| 6-Month Change | -18.59% |
| 5-Year Change | -85.21% |
| 10-Year Change | -83.54% |
| Total Return (1Y) | -14.39% |
| Total Return (5Y CAGR) | -36.11% |
| Max Drawdown (1Y) | -48.91% |
| Max Drawdown (3Y) | -81.47% |
| Sharpe Ratio (1Y) | -0.10 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $0.35 |
| 200-Day Average | $0.36 |
| 52-Week Range | $0.22 to $0.58 |
| RSI (14 Days) | 38.6 |
| Average Volume (20 Days) | 118.62K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.06x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 2.06x |
|---|---|
| Quick Ratio | 0.84x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -102.21% over the last 12 months, against a 5-year average of -97.19%.
| Return on Equity (ROE) | -102.21% |
|---|---|
| Return on Assets (ROA) | -53.83% |
| Return on Capital Employed (ROCE) | -101.43% |
| ROE (5Y Average) | -97.19% |
| ROA (5Y Average) | -56.31% |
| Asset Turnover | 1.20x |
| Inventory Turnover | 0.64x |
| Receivables Turnover | 8.40x |
| Cash Conversion Cycle | 261 days |
Scores
MLSS has an Altman Z-Score of -22.42, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -22.42 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $9.28M over the last 12 months is up 3.93% from the 12 months before.
| Revenue | $9.28M |
|---|---|
| Revenue Growth (YoY) | +3.93% |
| Gross Profit | $6.58M |
| Operating Income | -$3.72M |
| Pretax Income | -$3.74M |
| Net Income | -$3.74M |
| EBITDA | -$3.52M |
| EBIT | -$3.72M |
| Reported EPS (TTM) | -$0.04 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 52.74% of the $6.94M in total assets.
| Cash and Equivalents | $1.32M |
|---|---|
| Total Debt | $0 |
| Net Cash | $1.32M |
| Net Cash Per Share | $0.01 |
| Working Capital | $3.49M |
| Shareholder Equity | $3.66M |
| Book Value Per Share | $0.04 |
| Tangible Book Value | $3.63M |
| Tangible Book Per Share | $0.04 |
| Total Assets | $6.94M |
| Total Liabilities | $3.29M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $10.55K of capital spending, operating cash flow left -$1.48M of free cash flow.
| Operating Cash Flow | -$1.47M |
|---|---|
| Capital Expenditures | $10.55K |
| Free Cash Flow | -$1.48M |
| FCF Per Share | -$0.02 |
| Depreciation and Amortization | $197.37K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -40.04%, against a 5-year average of -77.19%.
| Gross Margin | 70.91% |
|---|---|
| Operating Margin | -40.04% |
| Pretax Margin | -40.27% |
| Net Margin | -40.27% |
| EBITDA Margin | -37.91% |
| EBIT Margin | -40.04% |
| FCF Margin | -15.96% |
| Gross Margin (5Y Average) | 66.40% |
| Operating Margin (5Y Average) | -77.19% |
| Net Margin (5Y Average) | -71.15% |
Growth
Revenue grew 0.63% a year over 3 years.
| Revenue Growth (3Y CAGR) | +0.63% |
|---|---|
| Revenue Growth (5Y CAGR) | +10.54% |
| Book Value Per Share Growth (2Y CAGR) | -41.09% |
| Tangible Book Per Share Growth (2Y CAGR) | -41.21% |
Dividends and Yields
MLSS does not pay a dividend. Its free cash flow yield is -5.58%.
| FCF Yield | -5.58% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-3 reverse split on Jan 14, 2004.
| Last Split Date | Jan 14, 2004 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:3 |
Peer Position
Against 11 similar companies, MLSS has the 8th highest P/S.
P/S RatioPeer median 3.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +4.84%
| P/S Ratio | 2.9x vs 3.1x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +3.93% vs +4.84% median |
Analyst Forecast
Consensus estimates put revenue growth at 12.46% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +12.46% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MLSS
What is MLSS's market cap?
Milestone Scientific has a market cap of $26.64M. Its enterprise value, which adds debt and subtracts cash, is $25.32M.
How many shares of MLSS are outstanding?
Milestone Scientific has 93.91M shares outstanding. The count is up 14.08% from a year earlier.
Does MLSS pay a dividend?
No. Milestone Scientific does not pay a dividend.
How much debt does MLSS have?
Milestone Scientific has $0 of total debt and $1.32M of cash and equivalents, a net cash position of $1.32M.
MLSS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors